The European pharmaceutical and biotechnology field this year is undergoing one of the most significant transformations in several decades. For years, the EU has been encountered with an innovation-access paradox. In other words, the Old Continent was home to first class research, but it was falling behind in market speed and equal patient access. As of now, the legislation is becoming clearer. With the formal publication of the Pharma Package texts in March 2026 and the unveiling of the Biotech Act, Brussels is aiming to achieve a “health union” by further integrating local markets. This model attempts to trade off shorter baseline protection periods for regulatory speed and innovation bonuses.
The Pharmaceutical Package and New Incentives
The final texts of the Pharma package represent a rewrite of the market’s rules of conduct. The core philosophy has shifted from protection to conditional rewards. Firstly, standard regulatory data protection has been changed to 8 years: it is now a baseline number. Companies can earn extensions, under some circumstances reaching up to 12 years, if they meet specific Union interests, such as launching the product in all 27 Member States, addressing an unmet medical need, or conducting comparative clinical trials. Additionally, to combat antimicrobial resistance, the EU has introduced a contentious tool: the Exclusivity Voucher. Developers of priority antibiotics can receive a 12-month extension of data exclusivity under new rules, which they can either use for another product in their portfolio or sell to another company. For major pharmaceutical market players, these vouchers might become a significant new asset class in future M&A negotiations.
Another novelty is the recognition of “breakthrough” orphan medicines, which are now eligible to receive 11 years of market exclusivity, compared with 9 years for standard orphan drugs. This way, the EU attempts to incentivise innovators that use a brand-new mechanism to treat a disease rather than manufacturers of refinement drugs that are similar to those already available on the market. In the past, many companies spent their budgets making the latter as they were regarded as safer investments. The new rules are made to change that conception. By offering much longer protection period and bigger bonuses to new pharmaceutical breakthroughs, the EU is making it more profitable for a company to develop entirely new cures, rather than simply releasing another version of existing medicine.
The Biotech Act
While the Pharma Package fixes the old rules, the Biotech Act unveiled in December last year and the upcoming Biotech Act II – expected in the Q3 2026 – are designed to build new industrial infrastructure required for scaling biomanufacturing. Building up on both Letta and Draghi reports, the Commission aims to rejuvenate EU biotech industry from its decadence – when 66 out of 67 companies chose to list their IPO outside EU in the past 6 years – into a competitive firepower. To achieve this, much like the strategic projects in other critical sectors, specific biotech initiatives can now apply for strategic status which gives them additional regulatory benefits. This status could grant them a fast-tracked permitting process at a single point of contact in the administration, cutting through the red tape of all of 27 member states. The Act proposes a 12-month extension to Supplementary Protection Certificates for biotech-derived and advanced therapy medicinal products, a move which was considered a major win for the industry players. This is expected to provide a critical buffer against the time lost during complex manufacturing and trial phases. The Act slashes the authorisation timeline for multinational clinical trials from 106 to 75 days and goes as low as 47 days for low-risk trials. The introduction of a Single Core Dossier means that sponsors operating across all Member States can now bypass the need for 27 versions of filing paperwork.
Data and Infrastructure
The European Health Data Space Regulation, which entered into force in 2025, is transitioning into implementation phase in 2026. The EHDS establishes a unified digital framework that consists of two components: Primary and Secondary Use. The former regulates the exchange of medical records for direct patient treatment. For businesses, the Primary Use is less important in comparison to the massive opportunities in Secondary Use, which will enable the companies to look at batches of anonymous data points that they can use to find patterns and further incorporate them to develop new drugs or train AI models. Until now, if a biotech company wanted to train an AI assistant to spot cancer, they had to ask every single hospital for data. The process was time consuming and even at ties redundant. Under the EHDS, companies now have a legal way to request access to massive cross-border sets of health data. To protect patients, the data is anonymous, and names and addresses are stripped away. The industry players will get the medical insights without the personal identities, which might turn Europe into the one of the most attractive places in the world to train medical AI as the scope of available data is expected to be massive and diverse.
Developing a new medical tool normally takes several years and significant financial committment (often millions of euros), with the constant fear that all nesessary permits might not be granted at the end. The Biotech Act introduces “regulatory sandboxes” to solve this problem. A sandbox is a safe space where a company can test a new idea, such as an AI-driven diagnostic app, under the watchful eye of regulators while still building the app. Instead of waiting a decade for final approval, companies can get proactive feedback in the process. Regulators will give their thoughts on the project in real-time as it might significantly lower the risk of failing at the finish line and help corporations get their product to patients much faster.
The Immediate Horizon
The European Medical Agency will launch its Implementation Gateway, a digital platform providing technical guidance for the full application of the new Pharma rules in the Q2 of 2026. Companies can begin stress-testing their portfolios now, e.g. see whether the drug is launched across all member states if the goal is to get the full 12 years of data protection. Another item to keep a close eye on is the proposal of Biotech Act II. While the first part of the Biotech package is focused on health, Biotech II is expected to expand these fast-track rules to similar areas, such as agri-biotech, energy-biotech, or defence-biotech.
Additionally, until the end of the year, the Commission is expected to publish the first list of critical medicines under the proposed Critical Medicines Act. If a company’s product is included, they can expect stricter obligations related to the security of the supply chain. For instance, pharmaceutical players might be legally required to always keep several months of extra stock in EU warehouses or report every roadblock in the supply chain to European authorities. To ease the financial burden imposed by these rules, the EU offers compensation through joint procurement between Member States, the government will award big contracts guaranteeing predictable multi-year revenue. For critical medicines, the EU will not purchase the cheapest offer, but instead will be guided by the “most economically advantageous tender”, meaning they will pick a company that might even be more expensive as long as the production is set in Europe or has a better security of supply.
The Expectation for Market Players
In 2026, the biotech and pharmaceutical sectors are moving away from being automatically eligible for protection towards a system where that protection will need to be earned. The requirement to launch in all 27 Member States may impose additional burden for some companies. Middle-market firms should consider partnering with local distributors early to ensure they don’t miss out on the extensions that could make a project more profitable. With Biotech II arriving this fall, corporations should evaluate whether their technologies have applications beyond healthcare, such as in bio-based materials or industrial enzymes. The funding pools for industrial biotech are often less popular than those for traditional pharmaceuticals. Lastly, the new Substances of Human Origin Regulation (nearing its 2027 application) places higher personal responsibility on management for the quality and safety of blood, cell, and tissue products.
The 2026 regulatory environment will reward speed and transparency. The companies that will thrive are likely those that stop viewing compliance as a mere legal cost and start using the new fast-track strategic labels as a competitive tool to reach the market before their global rivals do the same.
Read the full Regulatory Horizon Report by B&K Agency:
